Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: A randomised double-blind intervention study

4Citations
Citations of this article
59Readers
Mendeley users who have this article in their library.

Abstract

Aim To evaluate the safety of 1.25mg and 2mg intravitreal ziv-aflibercept (IVZ) in Ghanaian eyes with choroido-retinal vascular diseases. Design Prospective, randomised, double blind, interventional study. Methods Twenty patients with centre involving macular oedema in diabetic retinopathy, retinal vein occlusion, and neovascular age-related macular degeneration were assigned to 2 groups receiving 3 doses of 1.25mg/0.05ml (group 1) and 2mg/0.08ml IVZ (Group 2) at 4 weekly intervals. Safety data was collected after 30 minutes, 1 and 7 days, and 4, 8 and 12 weeks after injection. Changes in continuous variables were compared using paired t-test and categorical variables were compared using chi-square test of proportions. Repeated-Measures ANOVA with nesting test was used to compare variations in continuous variables by IVZ dose over time. Primary outcome measures were ocular and systemic adverse events at 4 weeks. Results Eleven females and nine males, with mean age of 63.2± 7.3 years were included. Ocular adverse events included subconjunctival haemorrhage in 1 eye, intraocular pressure (IOP) >21mm Hg at 30 minutes in 6 eyes and mild pain in 3 eyes at 1-day. There was no significant difference in IOP rise between the 2 groups at 30 minutes (p = 0.21). No other ocular or systemic adverse events were observed. There was significant improvement in the best corrected visual acuity (LogMAR) from 0.95±0.6 to 0.6±0.4 (p<0.01) and 0.47±0.3 (p<0.01), reduction in central subfield foveal thickness from 405.9±140 um at baseline to 255.6±75 um (p<0.01) and 238±88 um (p<0.01) at 4 and 12 weeks respectively, although no difference was observed between the 2 groups (p = 0.34). Conclusion IVZ at 1.25mg and 2mg had similar safety profiles, and did not have any major unexpected adverse events. Further studies with larger cohorts are required to confirm efficacy.

References Powered by Scopus

Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop

3674Citations
N/AReaders
Get full text

Global estimates of visual impairment: 2010

2797Citations
N/AReaders
Get full text

Non-communicable diseases in sub-Saharan Africa: What we know now

426Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series

4Citations
N/AReaders
Get full text

Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications

1Citations
N/AReaders
Get full text

Effectiveness of the Use of Three-Dose Intravitreal Ziv-Aflibercept in the Management of Diabetic Macular Edema in a Real-Life Setting

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Braimah, I. Z., Kenu, E., Amissah-Arthur, K. N., Akafo, S., Kwarteng, K. O., & Amoaku, W. M. (2019). Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: A randomised double-blind intervention study. PLoS ONE, 14(10). https://doi.org/10.1371/journal.pone.0223944

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 15

75%

Professor / Associate Prof. 2

10%

Researcher 2

10%

Lecturer / Post doc 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 10

48%

Nursing and Health Professions 6

29%

Biochemistry, Genetics and Molecular Bi... 3

14%

Pharmacology, Toxicology and Pharmaceut... 2

10%

Save time finding and organizing research with Mendeley

Sign up for free